We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HNR1:XETRHannover Rueck SE Analysis

Data as of 2026-05-25 - not real-time

€242.80

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Hannover Rück is trading at €242.8, well below its DCF‑derived fair value of roughly €430 and the consensus 12‑month target of €285‑312, implying an upside of 15‑30 %. The stock’s PE of 10.2 is markedly lower than the industry average of 16.8, while the dividend yield of 5.2 % is supported by a modest 29 % payout ratio, indicating strong sustainability. Recent earnings have surged, meeting the higher profit guidance set in November, and analysts have upgraded the target price, reinforcing the bullish narrative. On the balance sheet, the company holds €7.7 bn in cash against €4.1 bn of debt, delivering a comfortable net‑cash position and a low debt‑to‑equity ratio of 28 %. Profitability metrics are solid, with ROE above 21 % and operating margins near 10 %, despite a 22 % revenue contraction.
Technical indicators are mixed: the price sits beneath the 20‑, 50‑ and 200‑day moving averages, yet the MACD histogram is positive and the RSI at 40 hints at a possible rebound from short‑term oversold conditions. Volume has been tapering, and 30‑day volatility remains high at 25 %, suggesting price swings may continue. The beta of 0.11 underscores minimal correlation with broader market moves, while the “Extreme Greed” sentiment in the fear‑greed index reflects a favorable market backdrop. In sum, the combination of deep valuation discounts, robust dividend, solid fundamentals and positive earnings news positions Hannover Rück as an attractive entry point, albeit with short‑term price volatility to watch.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Technical bounce potential (MACD bullish, RSI near oversold)
  • Strong dividend yield with low payout ratio
  • Positive earnings surprise and raised profit target

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Valuation upside of ~20 % versus analyst targets
  • Sustainable cash flow and net‑cash balance sheet
  • Low market beta reducing systemic risk

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Consistently high ROE and solid profit margins
  • Defensive insurance business with diversified geography
  • Reliable dividend policy supporting total return

Key Metrics & Analysis

Financial Health

Revenue Growth-22.80%
Profit Margin11.82%
P/E Ratio10.2
ROE21.71%
ROA4.14%
Debt/Equity27.86
P/B Ratio2.1
Op. Cash Flow€5.9B
Free Cash Flow€3.7B
Industry P/E16.8

Technical Analysis

TrendNeutral
RSI39.9
Support€233.20
Resistance€272.00
MA 20€247.76
MA 50€260.01
MA 200€253.87
MACDBullish
VolumeDecreasing
Fear & Greed Index91.63

Valuation

Fair Value€430.49
Target Price€285.40
Upside/Downside17.55%
GradeUndervalued
TypeValue
Dividend Yield5.18%

Risk Assessment

Beta0.11
Volatility25.11%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.